

**Materials for this course will release 04/12/2023**

---

**Infectious Diseases Pharmacy Specialty Recertification Literature Study: Module 1A-B (Cert # L239192)**

**Teaser:** The Literature Study Module provides immediate access to peer-selected, contemporary articles that are relevant to specialty practice. After learners review the content, they must successfully complete an online assessment to earn recertification credit.

**Tag: Infectious Diseases**



**ACPE Numbers:** Various – see listing below

**Pre-Sale Date:** 03/15/2023

**Content Release Date:** 04/12/2023

**Expiration Dates:** 04/09/2024

**Activity Type:** Application-based

**CE Credits:** 8.0 contact hours (BPS and ACPE)

**Activity Fee:** \$55 (ASHP member); \$110 (non-member)

**Accreditation**



The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.



The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

**Target Audience**

These Literature Studies are designed to help board-certified pharmacists who are seeking recertification contact hours to maintain their Board of Pharmacy Specialties (BPS).

**Activity Overview**

The Literature Study Module is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This module consists of 2 online home study activities (see table below). Each activity is designed to assess the learners' ability to analyze and apply peer-selected contemporary articles to practice.

Module 1A: Gram-Negative Infections and Fever of Unknown Origin -- This module focuses on treatment of antimicrobial resistant gram-negative infections and fever of unknown origin.

Module 1B: Update in Infectious Diseases Topics -- This module focuses on various topics including treatment duration, management of cryptococcal meningitis and *Clostridioides difficile*, and tele-antimicrobial stewardship programs.

**Materials for this course will release 04/12/2023**

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this Literature Study, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.

These activities are part of the ASHP professional development program for BCIDP recertification approved by the BPS.

**Recertification Credit\***

Board certified pharmacists are eligible to receive up to 8 hours of recertification credit for completing this module. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Learning Activity	ACPE Number	Contact Hours	Assessment Pass Point
Infectious Diseases Pharmacy Specialty Recertification Literature Study Module 1A: Gram-Negative Infections and Fever of Unknown Origin	0204-9999-23-960-H01	3	80%
Infectious Diseases Pharmacy Specialty Recertification Literature Study Module 1B: Update in Infectious Diseases Topics	0204-9999-23-961-H01	5	72%
<b>Recertification Assessment Group</b>		8 BPS	

**Articles and Learning Objectives**

**Module 1A: Gram-Negative Infections and Fever of Unknown Origin**

**ACPE Number: 0204-9999-23-960-H01**

This module focuses on treatment of antimicrobial resistant Gram-negative infections and fever of unknown origin.

Tamma PD, Aitken SL, Bonomo RA et al. Infectious Diseases Society of America guidance on the treatment of AmpC  $\beta$ -lactamase-producing Enterobacterales, carbapenem-resistant *Acinetobacter baumannii*, and *Stenotrophomonas maltophilia* infections. *Clin Infect Dis.* 2022; 74(12):2089-2114.

Learning Objectives:

- Describe the Infectious Diseases Society of America (IDSA) guidance on the treatment of AmpC  $\beta$ -lactamase-producing Enterobacterales (AmpC-E), carbapenem-resistant *Acinetobacter baumannii* (CRAB), and *Stenotrophomonas maltophilia* (*S. maltophilia*) infections
- Develop recommendations for the treatment of infections caused by AmpC  $\beta$ -lactamase-producing Enterobacterales (AmpC-E), carbapenem-resistant *Acinetobacter baumannii* (CRAB), or *Stenotrophomonas maltophilia* (*S. maltophilia*)

**Materials for this course will release 04/12/2023**

---

Sarzynski SH, Warner S, Sun J et al. Trimethoprim-sulfamethoxazole versus levofloxacin for *Stenotrophomonas maltophilia* infections: a retrospective comparative effectiveness study of electronic health records from 154 US hospitals. *Open Forum Infect Dis.* 2022; 9(2):ofab644.

Learning Objectives:

- Describe the study by Sarzynski and colleagues comparing trimethoprim-sulfamethoxazole (TMP-SMX) with levofloxacin for the treatment of bloodstream or lower respiratory tract infection caused by *Stenotrophomonas maltophilia*
- Develop antibiotic therapy recommendations for adults hospitalized with bloodstream or lower respiratory tract infection caused by *Stenotrophomonas maltophilia*

Haidar G, Singh N. Fever of unknown origin. *N Engl J Med.* 2022; 386:463-477.

Learning Objectives:

- Describe the febrile response and etiology, diagnosis, and management of fever of unknown origin (FUO)
- Develop recommendations for the diagnostic work up and management of patients with fever of unknown origin (FUO)

### **Module 1B: Update in Infectious Diseases Topics**

**ACPE Number: 0204-9999-23-961-H01**

This module focuses on various topics including treatment duration, management of cryptococcal meningitis and *Clostridioides difficile*, and tele-antimicrobial stewardship programs.

Drekonja DM, Trautner B, Amundson C et al. Effect of 7 vs 14 days of antibiotic therapy on resolution of symptoms among afebrile men with urinary tract infection: a randomized clinical trial. *JAMA.* 2021; 326(4):324-331.

Learning Objectives:

- Describe the study by Drekonja and colleagues evaluating the resolution of urinary tract infection symptoms in afebrile men from the use of 7 days or 14 days of antibiotic therapy
- Develop recommendations for the duration of antibiotic therapy for adult men with urinary tract infection

Bielicki JA, Stohr W, Barratt S et al. Effect of amoxicillin dose and treatment duration on the need for antibiotic re-treatment in children with community-acquired pneumonia: the CAP-IT randomized clinical trial. *JAMA.* 2021; 326(17):1713-1724.

Learning Objectives:

- Describe the CAP-IT trial by Bielicki and colleagues of the effect of amoxicillin dosage and treatment duration on the need for antibiotic re-treatment in children with community-acquired pneumonia (CAP)
- Develop recommendations for the dosage and duration of treatment with amoxicillin of young children with community-acquired pneumonia (CAP)

Jarvis JN, Lawrence DS, Meya DB et al. Single-dose liposomal amphotericin B treatment for cryptococcal meningitis. *N Engl J Med.* 2022; 386(12):1109-1120.

Learning Objectives:

- Describe the Ambition trial by Jarvis and colleagues of liposomal amphotericin B treatment for cryptococcal meningitis
- Develop recommendations for the use of liposomal amphotericin B in human immunodeficiency virus (HIV)-positive adults with cryptococcal meningitis

**Materials for this course will release 04/12/2023**

---

Johnson S, Lavergne V, Skinner AM et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of *Clostridioides difficile* infection in adults. *Clin Infect Dis*. 2021; 73(5):e1029-e1044.

Learning Objectives:

- Describe the clinical practice guideline with a 2021 focused update from the Infectious Diseases Society of America and Society for Healthcare Epidemiology of America on the management of *Clostridioides difficile* infection in adults
- Develop recommendations for the management of *Clostridioides difficile* infection in adults

Andrzejewski C, McCreary EK, Khadem T et al. Tele-antimicrobial stewardship programs: a review of the literature and the role of the pharmacist. *J Am Coll Clin Pharm*. 2021; 4(8):1016-1033.

Learning Objectives:

- Describe challenges faced by hospitals in providing antimicrobial stewardship and models for inpatient tele-antimicrobial stewardship programs (TASPs)
- Develop recommendations for an inpatient tele-antimicrobial stewardship program (TASP)

#### Faculty

<https://www.rxcertifications.org/Infectious-Diseases/Course-Faculty>

##### **Travis J. Carlson, PharmD, BCIDP**

Assistant Professor of Clinical Sciences  
High Point University  
Fred Wilson School of Pharmacy  
High Point, North Carolina

##### **Kevin W. Garey, PharmD, MS, FASHP\***

Professor and Chair  
University of Houston  
Houston, Texas

##### **Sarah B. Green, PharmD, BCPS, BCIDP, AAHIVP**

Clinical Pharmacy Specialist, Infectious Diseases  
Emory University Hospital  
Atlanta, Georgia

##### **Jerika Lam, PharmD, APh, AAHIVP, FCSHP\***

Associate Professor of Pharmacy Practice  
Chapman University School of Pharmacy  
Irvine, California

##### **Misty Miller, PharmD, BCPS, AAHIVP**

Associate Professor  
University of Oklahoma College of Pharmacy  
Oklahoma City, Oklahoma

##### **Jessica Robinson, PharmD, BCPS, BCIDP**

Associate Professor / Associate Director of Antimicrobial Stewardship  
University of Charleston School of Pharmacy / Charleston Area Medical Center  
Charleston, West Virginia

##### **Kayla R. Stover, PharmD, BCPS, BCIDP, FCCP, FIDSA\***

Professor of Pharmacy Practice  
University of Mississippi School of Pharmacy  
Jackson, Mississippi

##### **Evan Zasowski, PharmD, MPH, BCIDP, BCPS\***

Assistant Professor  
Touro University California College of Pharmacy  
Vallejo, California

**\* Content Matter Experts**

**Materials for this course will release 04/12/2023**

---

#### Reviewers

Susan R. Dombrowski, MS, RPh  
Kristi Hofer, PharmD

#### Field Testers

Hakeem Abayomi, BS, PharmD, BCPS, BCPPS, BCIDP, BCCCP

Jill Argotsinger, PharmD, BCIDP

Linette Beers, PharmD

Jordan Chiasson, PharmD, BCIDP

Philip Chung, PharmD, MS, BCPS, BCIDP

Jessica Cottreau, PharmD, BCPS

Marco Custodio, PharmD, MS, BCIDP, AAHIVP

Melissa Danek, PharmD, BCPS, BCIDP

Alaina DeKerlegand, PharmD, BCIDP

Zach DeLanoit, PharmD, BCIDP

Alex Dominguez, PharmD, MAS, BCPS, BCIDP

Jessica Foley, PharmD, BCIDP

Mercedes Fraga, PharmD, BCPS, BCIDP, BCCCP

Lawahidh Hasham, PharmD

James Hughes, PharmD, BCPS, BCIDP

Judith Ikwuagwu, BS, PharmD, BCPS, BCIDP

Caroline Jozefczyk, PharmD, BCIDP

Meghan Kamath, PharmD, BCIDP

Bronagh Keane, RPh, BCPS, BCIDP

Michael Kent, PharmD, BCIDP

Brett Keskes, PharmD, BCIDP

Julia Kufel, PharmD, BCIDP

Jamie Legaspi, PharmD, BCIDP

Adrienne Ma, PharmD, BCIDP

Neha Manchandia, PharmD, BCIDP

Kassandra Marsh, PharmD

Jessica Michal, PharmD, BCIDP, AAHIVP

Jessica Miller, PharmD, BCIDP

Sarah Moore, PharmD, BCIDP

Mandee Noval, PharmD, BCIDP

Sonal Patel, PharmD, BCIDP

Anna Poston-Blahnik, PharmD, BCIDP, AAHIVP

Yinghui Pu, PharmD, PhD, BCPS, BCIDP

Alanna Rufe, PharmD, BCIDP

Julia Sapozhnikov, PharmD, BCIDP

Punit Shah, BCPS, BCIDP

Stephanie Shulder, PharmD, BCIDP

Andrea Simon, PharmD, BCIDP

Jessica Sobnosky, PharmD, BCPS, BCIDP

Kady Stoyanov, PharmD, BCIDP

Caroline Taazieh, PharmD, BCPS, BCCCP, BCIDP, BCCP

Jessica Thompson, PharmD, BCPS, BCIDP

Natalie Tucker, PharmD, BCPS, BCIDP

Obioma Ubaka, BCPS, BCIDP

Amber Welborn, PharmD, BCIDP, AAHIVP

Solomon Winans, PharmD, BCIDP

Linda Yang, PharmD, BCIDP

Min Zhang, PharmD, BCPS, BCIDP

#### Disclosures

In accordance with our accreditor's Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.

The following persons in control of this activity's content have relevant financial relationships:

Sarah Green: Merck & Co., Inc., research grant

All other persons in control of content do not have any relevant financial relationships with an ineligible company.

**Materials for this course will release 04/12/2023**

---

As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.

**Methods and CE Requirements**

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

- Complete the attestation statement
- Review all content
- Complete and pass the assessments
- Complete the evaluations

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

**System Technical Requirements**

Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites.

View the [minimum technical and system requirements](#) for learning activities.

**Development**

ASHP collaborates with ACCP collaborate on infectious disease pharmacy activities.